| FLOWCYTOMETRY |
| B5073 |
IMMUNOPHENOTYPING OF LEUKAEMIA BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface/intracellular markers to evaluate and diagnose specific Acute Leukaemia types based on the clinical diagnosis and other primary lab findings. Report interpreted based on the percentage of expression of CD markers.
Markers used for AML, ALL (T-ALL, Pre-B-ALL):
Cell surface: CD56, CD13, CD34, CD19, CD10, CD38, CD20, CD64, CD33,CD11c, CD117, CD11b, CD14, HLADR
Cytoplasmic: MPO, cCD79a, cCD3, TdT
Secondary Markers for AML –M6 and AML-M7 CD61, CD41, CD235a, CD36
Secondary Markers for T-ALL CD4, CD1a, CD5, CD10, CD2, CD3, CD8
Gating Strategy: CD45/SSC Gating. |
5-6 ml of Sodium heparin (Green top) anti-coagulated peripheral blood, bone marrow samples.
2-3 ml of other body fluids pericardial fluid, ascitic fluid, CSF, pleural fluid.
Storage:
Bone marrow samples in room temperature.
Peripheral Blood can be stored at 4°C for processing next day.
CSF must be freshly processed.
|
| B5076 |
IMMUNOPHENOTYPING OF LYMPHOMA BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose specific Lymphomas based on the clinical diagnosis and other primary lab findings.
Markers used for Lymphoma diagnosis (T cell,B-cell):
CD23, CD10, CD79b, CD19, CD200, CD43, CD20 , LAMBDA, KAPPA, CD5, CD19, CD3, CD38, CD7, IgM, IgD, CD4, CD8
Secondary Markers for BURKITT'S LYMPHOMA (ALL-L3): Lambda, Kappa,CD20
Secondary Markers for B-NHL: CD25, CD103, CD11c, CD19, CD123, CD22, CD45, CD19
Secondary Markers for T-NHL: CD57, CD16, CD56, CD25, TCRαβ, TCRγδ, CD2.
Gating Strategy: CD45/SSC, CD19/CD45 and CD3/CD45 Gating. |
5-6 ml of Sodium heparin (Green top) anti-coagulated bone marrow / peripheral blood samples
2-3 ml of other body fluids pericardial fluid, ascitic fluid, CSF, pleural fluid
Storage:
Bone marrow samples in room temperature.
Peripheral Blood can be stored at 4°C for processing next day.
CSF must be freshly processed.
|
| B5074 |
IMMUNOPHENOTYPING OF ALPS (DOUBLE NEGATIVE T CELLS) BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose ALPS based on the clinical diagnosis and other primary lab findings.
Markers used for ALPS Diagnosis:
CD3, TCRαβ, CD4, CD8, CD56, CD20 on healthy control and patient.
Gating Strategy: FSC/SSC for total lymphocytes or CD3/SSC plot for gated T lymphocytes. |
5-6 ml of Sodium Heparin anti-coagulated (Green top) peripheral blood samples of a patient and healthy control.
|
| B5074 |
IMMUNOPHENOTYPING FOR LAD1 (LEUKOCYTE ADHESION DEFICIENCY) BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose LADbased on the clinical diagnosis and other primary lab findings.
Markers used for LAD Diagnosis:
CD18, CD11a, CD11b, CD11c on patient and healthy control
Gating Strategy: FSC/SSC on granulocytes. |
5-6 ml of Sodium Heparin anti-coagulated (Green top) peripheral blood samples of a patient and healthy control.
|
| B5074 |
IMMUNOPHENOTYPING OF SEVERE COMBINED IMMUNODEFICIENCY DISORDER (SCID) / LYMPHOCYTE SUBSET ANALYSIS BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose SCID / Analyze Lymphocyte subsetsbased on the clinical diagnosis and other primary lab findings. Report interpreted as absolute counts based on the percentage of expression of CD markers.
Markers used for SCID / Subset Analysis:
CD4, CD8, CD3, CD19, CD56, CD45
Gating Strategy: CD45/SSC on lymphocytes. |
5-6 ml of Sodium heparin anti-coagulated (Green top) peripheral blood sample of the patient. Stored at 4°C
|
| B5074 |
PLATELET IMMUNOPHENOTYPING FOR GLANZMANN’S THROMBASTHENIA (GT) BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose GTbased on the clinical diagnosis and other primary lab findings
Markers used for GT Diagnosis:
CD42a(GPIb/IX) and CD41a (GPIIb) and CD61 (GPIIIa) on healthy control and patient.
Gating Strategy: FSC/SSC on platelets |
5-6 ml of Sodium heparin anti-coagulated (Green top) peripheral blood samples of a patient and healthy control.
|
| B5074 |
DHR TEST FOR CHRONIC GRANULOMATOUS DISEASE (CGD)
Patient’s peripheral blood neutrophils are stimulated with a specific mitogen like PMA and the difference in fluorescence is used to diagnose CGD by comparing with a normal control
|
5-6 ml of Sodium Heparin anti-coagulated (Green top) peripheral blood samples of a patient and healthy control.
|
| B5075 |
FLOW CYTOMETRY FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Selective panels of antibodies are used for cell surface markers to evaluate and diagnose PNHbased on the clinical diagnosis and other primary lab findings.
Markers used for PNH Diagnosis:
FLAER (Alexa Fluor 488nm), CD59, CD11b, CD33, CD14, CD45 on patient and healthy control
Gating Strategy: CD59 and FLAER expression on patient neutrophils, monocytes and RBCs (FSC/SSC, CD45/SSC, CD33/SSC) |
5-6 ml of Sodium heparin anti-coagulated (Green top) peripheral blood samples of a patient and healthy control.
|
| B5081 |
CD34+ CELLS ENUMERATION
Enumeration of CD34 positive cells in PBSCT and BMT samples
Gating Strategy: ISHAGE gating strategy – CD34 kit based enumeration |
1mL of PBSC Samples / 5-6 ml of peripheral blood in sodium heparin anticoagulated (green top) tubes
|
| B5081 |
DLI - CD3 ENUMERATION
Enumeration of CD3 positive cells in PDLI sample to be given to the transplant recipient
Gating Strategy: ISHAGE gating strategy. |
5-6 ml of peripheral blood in sodium heparin anticoagulated (green top) tubes.
|
MINIMAL RESIDUAL DISEASE (MRD) FOR HEMATOLOGICAL MALIGNANCIES |
| B5080 |
MINIMAL RESIDUAL DISEASE DETECTION (MRD) FOR B CELL ALL
Selective panels of antibodies are used for cell surface markers to evaluate minimal residual diseaseby utilizing an LAIP based DFN approach. Each sample is processed in two tubes and 1.5 million events are acquired per tube
Markers Used for MRD of B CELL ALL: CD20, CD10, CD19, CD45, CD34, CD58, CD38, CD81, CD123, CD200, CD66c, CD73
Gating Strategy: CD45/SSC, CD19/CD5 and CD19/SSC Gating. |
5-6 ml of Sodium heparin (Green top) anti-coagulated bone marrow samples.
|
| B5096 |
MINIMAL RESIDUAL DISEASE DETECTION (MRD) FOR MULTIPLE MYELOMA
Selective panels of antibodies are used for cell surface and cytoplasmic markers to evaluate minimal residual diseaseby utilizing the immunophenotypic difference between normal and clonal plasma cells. Each sample is processed in two tubes and 1.5 million events are acquired per tube
Markers Used for MRD of B CELL ALL: CD38, CD138, CD19, CD45, CD27, CD81, CD56, CD117, cytoKAPPA AND cytoLAMBDA
Gating Strategy: FSC/SSC, CD38/CD45 and CD38/CD138 Gating
|
5-6 ml of Sodium heparin (Green top) anti-coagulated bone marrow samples.
Myeloma samples for MRD should be processed on the same day
|
| B5109 |
MINIMAL RESIDUAL DISEASE DETECTION (MRD) FOR T CELL ALL
Selective panels of antibodies are used for cell surface and cytoplasmic markers to evaluate minimal residual disease. Each sample is processed in two tubes and 1.5 million events are acquired per tube.
Markers Used for MRD of B CELL ALL: CD3, cytoCD3, CD7, CD45, CD34, CD56, CD48, CD99, CD38, CD5, CD4, CD8
Gating Strategy: CD45/SSC, CD7/CD45, cytoCD3/CD56 and CD3/cytoCD3 Gating |
5-6 ml of Sodium heparin (Green top) anti-coagulated bone marrow samples. |
| B5110 |
MINIMAL RESIDUAL DISEASE DETECTION (MRD) FOR AML(WAS) BY FLOWCYTOMETRY
Selective panels of antibodies are used for cell surface markers to evaluate minimal residual diseaseby utilizing an LAIP based DFN approach. Each sample is processed in two tubes with 10 antibodies and 1.5 million events per tube.
Markers Used for MRD of B CELL ALL: CD45, CD34, CD117, HLADR, CD64, CD14, CD33, CD13, CD11b, CD7, CD19, CD56, CD38, CD123, CD36, CD15
Gating strategy: CD45/SSC, CD19/CD5 and CD19/SSC Gating |
5-6 ml of Sodium heparin (Green top) anti-coagulated bone marrow samples. |
Apart from the other tests, flow cytometry analysis is also done as a part of specific transplantation-related procedures like TCRαβ depletion, CD45RA depletion etc
